Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
08 févr. 2024 15h17 HE
|
Spherix Global Insights
Exton, Pennsylvania, Feb. 08, 2024 (GLOBE NEWSWIRE) -- As Age-Related Macular Degeneration (AMD) Awareness Month unfolds, illuminating the visual challenges faced by millions of Americans with AMD,...
Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed Therapeutics, EyeBiotech, Novartis, Hoffmann-La Roche, Kyowa Kirin, Skyline Therapeutics
31 janv. 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Wet-Age Related Macular Degeneration Market to Observe Stupendous Growth by 2032, Predicts DelveInsight | Key Players - AbbVie, Opthea, AffaMed...
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
14 déc. 2023 07h05 HE
|
Clearside Biomedical, Inc.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
ROSEN, A RESPECTED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
04 déc. 2023 15h46 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
19 nov. 2023 23h19 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
OTLK INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OTLK
16 nov. 2023 14h09 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 16, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Outlook Therapeutics, Inc. (NASDAQ: OTLK) between December...
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
02 nov. 2023 07h05 HE
|
Clearside Biomedical, Inc.
Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg.
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
01 nov. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
16 oct. 2023 07h05 HE
|
Clearside Biomedical, Inc.
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
18 sept. 2023 06h00 HE
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...